Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18983137 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18490030 | PAPN MUTANT AND COMPOSITION FOR SITE-DIRECTED MODIFICATION OF PAPN GENE AND APPLICATION THEREOF | October 2023 | January 2025 | Allow | 15 | 2 | 1 | No | No |
| 18320789 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18137110 | HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI | April 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18166447 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | February 2023 | November 2024 | Allow | 22 | 3 | 0 | Yes | No |
| 18107000 | IN VIVO Method for Generating Diversity in a Protein Scaffold | February 2023 | January 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18047233 | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | October 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17906781 | In vivo targeting of T cells for mRNA therapeutics | September 2022 | October 2025 | Abandon | 37 | 5 | 0 | Yes | No |
| 17818730 | RODENT MODEL OF MOOD DISORDERS | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17862668 | TREATMENT AND PREVENTION OF OCULAR NEURODEGENERATIVE DISORDER | July 2022 | February 2025 | Allow | 31 | 1 | 0 | No | No |
| 17744970 | ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLEY ISOLATED CELLS | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17739955 | Gene Editing to Improve Joint Function | May 2022 | May 2025 | Allow | 36 | 1 | 0 | No | No |
| 17734392 | HUMANIZED UNIVERSAL LIGHT CHAIN MICE | May 2022 | January 2026 | Allow | 44 | 1 | 0 | No | No |
| 17728874 | TRANSGENIC ANIMAL FOR PRODUCING DIVERSIFIED ANTIBODIES THAT HAVE THE SAME LIGHT CHAIN I | April 2022 | May 2025 | Allow | 37 | 2 | 0 | No | No |
| 17697623 | VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF | March 2022 | August 2025 | Allow | 41 | 1 | 0 | No | No |
| 17669839 | BACILLUS THURINGIENSIS TOXIN RECEPTORS AND USES THEREOF | February 2022 | December 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17574626 | AFFINITY MATURATED T CELL RECEPTORS AND USE THEREOF | January 2022 | September 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17565302 | ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF | December 2021 | January 2026 | Abandon | 49 | 1 | 0 | No | No |
| 17558052 | RECOMBINANT AAV-CRUMBS HOMOLOGUE COMPOSITION AND METHODS FOR TREATING LCA-8 AND PROGRESSIVE RP | December 2021 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17490765 | METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) | September 2021 | June 2025 | Allow | 44 | 2 | 0 | No | No |
| 17442759 | CAR FOR USE IN THE TREATMENT OF HVG DISEASE | September 2021 | September 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17481484 | PROTEIN HAVING NUCLEASE ACTIVITY, FUSION PROTEINS AND USES THEREOF | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17402233 | HTT REPRESSORS AND USES THEREOF | August 2021 | October 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17368266 | MANIPULATION OF IMMUNOGLOBULIN GENE DIVERSITY AND MULTI-ANTIBODY THERAPEUTICS | July 2021 | August 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17348356 | ADENO-ASSOCIATED VIRUS ANTIBODIES AND FRAGMENTS THEREOF | June 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17343563 | Muscle-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof | June 2021 | May 2025 | Allow | 47 | 2 | 0 | No | No |
| 17318316 | Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer | May 2021 | March 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17316266 | Genetically Modified Non-Human Animals And Methods Of Use Thereof | May 2021 | June 2024 | Allow | 38 | 1 | 0 | No | No |
| 17290843 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE | May 2021 | June 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17241839 | Gene Editing to Improve Joint Function | April 2021 | September 2024 | Allow | 40 | 1 | 0 | No | No |
| 17241171 | NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE | April 2021 | July 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17238710 | MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE | April 2021 | April 2025 | Allow | 48 | 2 | 0 | No | No |
| 17237475 | TOLEROGENIC DENDRITIC CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | April 2021 | July 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17209964 | COMMON LIGHT CHAIN MOUSE | March 2021 | April 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17277008 | TARGETED IMMUNOTOLERANCE | March 2021 | March 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17166398 | RNA VIRUSES FOR IMMUNOVIROTHERAPY | February 2021 | February 2024 | Abandon | 36 | 2 | 0 | Yes | No |
| 17163040 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | January 2021 | August 2025 | Abandon | 54 | 6 | 1 | Yes | Yes |
| 15734533 | PRODUCTION OF ANTIBODIES BY MODIFICATION OF AN AUTONOMOUS HEAVY CHAIN VARIABLE DOMAIN BY GENE CONVERSION | December 2020 | December 2025 | Allow | 60 | 3 | 1 | No | No |
| 15734189 | TRANSGENIC ANIMAL FOR PRODUCING DIVERSIFIED ANTIBODIES THAT HAVE THE SAME LIGHT CHAIN II | December 2020 | October 2025 | Allow | 58 | 3 | 0 | No | No |
| 17052835 | A pharmaceutical combination for use in the treatment of cancer | November 2020 | March 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17045266 | HINGES 1 AND/OR 4 MODIFIED DYSTROPHINS FOR DYSTROPHINOPATHY THERAPY | October 2020 | September 2025 | Abandon | 59 | 4 | 0 | Yes | No |
| 17042865 | AAV6 VARIANTS | September 2020 | January 2026 | Allow | 60 | 5 | 0 | Yes | No |
| 17042543 | LIVER TROPIC RECOMBINANT AAV6 VECTORS THAT EVADE NEUTRALIZATION | September 2020 | March 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17041359 | TALE-NUCLEASES FOR ALLELE-SPECIFIC CODON MODIFICATION AND MULTIPLEXING | September 2020 | January 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17030995 | IMMUNODEFICIENT NON-HUMAN ANIMAL | September 2020 | February 2025 | Allow | 53 | 4 | 0 | No | No |
| 17040017 | MODIFIED ONCOLYTIC ADENOVIRUSES | September 2020 | March 2026 | Allow | 60 | 4 | 1 | No | No |
| 16869416 | TRANSGENIC NON-HUMAN VERTEBRATE FOR THE IN VIVO PRODUCTION OF DUAL SPECIFICITY IMMUNOGLOBULINS OR HYPERMUTATED HEAVY CHAIN ONLY IMMUNOGLOBULINS | May 2020 | September 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16849954 | ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLY ISOLATED CELLS | April 2020 | July 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16626816 | ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF | December 2019 | May 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16657961 | COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX | October 2019 | September 2024 | Allow | 59 | 1 | 1 | Yes | No |
| 16596829 | GENOME EDITED CANCER CELL VACCINES | October 2019 | January 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16472794 | VIRUS AAV/IGF2, GENETIC TREATMENT METHOD AND USE THEREOF IN PROTEIN MISFOLDING-RELATED DISEASES, SUCH AS HUNTINGTON'S DISEASE | June 2019 | January 2026 | Allow | 60 | 6 | 0 | Yes | No |
| 16346614 | DNA Plasmids for the Fast Generation of Homologous Recombination Vectors for Cell Line Development | May 2019 | March 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16335653 | AUTOLOGOUS IRRADIATED WHOLE CELL TUMOR VACCINES LENTIVIRALLY ENGINEERED TO EXPRESS CD80, IL-15 AND IL-15 RECEPTOR ALPHA | March 2019 | August 2024 | Allow | 60 | 4 | 0 | No | No |
| 16327299 | TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES | February 2019 | August 2025 | Allow | 60 | 8 | 0 | No | No |
| 16265546 | METHOD FOR CHEMOSELECTION | February 2019 | March 2020 | Allow | 13 | 2 | 0 | No | No |
| 15960642 | HUMANIZED IL-7 RODENTS | April 2018 | January 2019 | Allow | 9 | 1 | 0 | No | No |
| 15947469 | FUSION MOLECULE BASED ON TAA VARIANT | April 2018 | March 2019 | Allow | 12 | 2 | 0 | No | No |
| 15763419 | TCR AND USES THEREOF | March 2018 | March 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 15870172 | Nucleic Acid Construct with a p16 Promoter that Causes a Prodrug Converting Enzyme to be Expressed Specifically in Senescent Cells | January 2018 | January 2020 | Allow | 24 | 2 | 0 | No | No |
| 15866374 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | January 2018 | September 2025 | Abandon | 60 | 6 | 1 | No | Yes |
| 15824230 | IMMUNIZATION OF AVIANS BY ADMINISTRATION OF NON-REPLICATING VECTORED VACCINES | November 2017 | March 2020 | Allow | 28 | 2 | 0 | Yes | Yes |
| 15568683 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR AND PROTEIN KINASE A BLOCKER | October 2017 | April 2024 | Allow | 60 | 7 | 0 | No | Yes |
| 15649797 | HUMANIZED IL-7 RODENTS | July 2017 | January 2018 | Allow | 6 | 1 | 0 | No | No |
| 15357021 | HUMANIZED IL-7 RODENTS | November 2016 | April 2017 | Allow | 4 | 1 | 0 | Yes | No |
| 15293710 | FUSION MOLECULE BASED ON NOVEL TAA VARIANT | October 2016 | January 2018 | Allow | 15 | 2 | 0 | No | No |
| 15103457 | TRANSGENIC NON-HUMAN MAMMAL THAT EXPRESSES HUMAN MMP2 | September 2016 | September 2017 | Allow | 15 | 1 | 0 | Yes | No |
| 15111483 | FUSION PROTEIN FOR INDUCING PLURIPOTENT STEM CELLS AND APPLICATION METHOD THEREOF | July 2016 | February 2018 | Allow | 19 | 2 | 1 | No | No |
| 15031169 | METHODS FOR GENETIC MODIFICATION OF STEM CELLS | April 2016 | November 2019 | Allow | 43 | 2 | 0 | Yes | No |
| 15132125 | ANIMAL MODEL AND METHOD FOR STUDYING GENE-GENE INTERACTIONS | April 2016 | December 2017 | Allow | 20 | 2 | 1 | Yes | No |
| 15048964 | COMPOSITION AND METHOD OF USING MIR-302 PRECURSORS AS DRUGS FOR TREATING ALZHEIMER'S DISEASES | February 2016 | August 2019 | Allow | 42 | 2 | 1 | Yes | No |
| 14418781 | CELL LINE DERIVED FROM THREAD-SAIL FILEFISH (STEPHANOLEPIS CIRRHIFER) | January 2015 | June 2017 | Allow | 28 | 2 | 0 | No | No |
| 14551538 | HUMANIZED IL-7 RODENTS | November 2014 | September 2015 | Allow | 10 | 3 | 0 | Yes | No |
| 14495614 | ENDOTHELIAL CELL-SPECIFIC POLYNUCLEOTIDES AND USE THEREOF | September 2014 | February 2015 | Allow | 5 | 2 | 0 | Yes | No |
| 14476626 | Novel Inflammation in Vivo Model | September 2014 | October 2015 | Allow | 13 | 2 | 0 | Yes | No |
| 14299480 | SURGICAL DEVICE FOR SKIN THERAPY OR TESTING | June 2014 | March 2015 | Allow | 9 | 2 | 0 | Yes | No |
| 14277969 | Muscle-Derived Cells (MDCs) for Treating Muscle- or Bone-Related Injury or Dysfunction | May 2014 | February 2016 | Allow | 21 | 2 | 0 | No | No |
| 14224274 | TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS | March 2014 | May 2015 | Allow | 14 | 1 | 0 | No | No |
| 14152673 | METHOD OF IN VITRO TOXICITY TESTING USING ISOLATED LIVER STEM CELLS | January 2014 | March 2014 | Allow | 2 | 0 | 0 | No | No |
| 14094109 | SYSTEM FOR PRODUCTION OF ANTIBODIES AND THEIR DERIVATIVES | December 2013 | November 2016 | Allow | 36 | 3 | 1 | Yes | No |
| 14086817 | PCP2 Mini-Promoters | November 2013 | December 2014 | Allow | 12 | 1 | 0 | No | No |
| 13795765 | Humanized IL-7 Rodents | March 2013 | December 2014 | Allow | 21 | 3 | 0 | Yes | No |
| 13769182 | USE OF HERPES VECTORS FOR TUMOR THERAPY | February 2013 | July 2017 | Allow | 53 | 4 | 1 | Yes | No |
| 13600711 | HERPES VIRUS STRAINS | August 2012 | October 2013 | Allow | 14 | 2 | 0 | No | No |
| 13558078 | NEURAL PROGENITOR CELL POPULATIONS | July 2012 | June 2017 | Allow | 59 | 3 | 1 | No | Yes |
| 13550488 | Tissue Specific Expression Of Antibodies In Chickens | July 2012 | November 2014 | Allow | 28 | 3 | 0 | Yes | No |
| 13532035 | MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS | June 2012 | May 2013 | Allow | 10 | 1 | 0 | Yes | No |
| 13448112 | Stem Cell Fusion Model of Carcinogenesis | April 2012 | March 2014 | Allow | 23 | 2 | 0 | No | No |
| 13212078 | RESCUE OF PHOTORECEPTORS BY INTRAVITREAL ADMINISTRATION OF AN EXPRESSION VECTOR ENCODING A THERAPEUTIC PROTEIN | August 2011 | December 2012 | Allow | 16 | 1 | 0 | No | No |
| 13161817 | MOUSE MODEL FOR DEPRESSION, SCHIZOPHRENIA AND ALZHEIMER'S DISEASE AND THE USE THEREOF | June 2011 | November 2013 | Allow | 29 | 2 | 0 | Yes | No |
| 13078119 | METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF T CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS | April 2011 | May 2014 | Allow | 37 | 3 | 0 | No | No |
| 13025449 | MUSCLE-DERIVED CELLS (MDCS) FOR AUGMENTING OR BULKING URETHRAL SPHINCTER-MUSCLE TISSUE | February 2011 | February 2014 | Allow | 36 | 2 | 1 | No | No |
| 12879931 | RECOMBINANT GENE WHICH ENHANCES THE ABILITY OF FISH TO TOLERATE LOW DISSOLVED OXYGEN STRESS AND THE USE THEREOF | September 2010 | June 2013 | Allow | 33 | 1 | 1 | Yes | No |
| 12517194 | CODON MODIFIED IMMUNOGENIC COMPOSITIONS AND METHODS OF USE | June 2010 | December 2013 | Allow | 55 | 2 | 1 | Yes | Yes |
| 12767086 | HUMAN MONOCLONAL ANTIBODIES TO EPIDERMAL GROWTH FACTOR RECEPTOR | April 2010 | October 2011 | Allow | 18 | 1 | 0 | Yes | No |
| 12758177 | HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA MODELED IN MOUSE BY TARGETED TCL1 EXPRESSION | April 2010 | September 2011 | Allow | 17 | 1 | 0 | Yes | No |
| 12755266 | MICROPARTICLE-BASED TRANSFECTION AND ACTIVATION OF DENDRITIC CELLS | April 2010 | September 2011 | Allow | 17 | 1 | 0 | Yes | No |
| 12716239 | MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS | March 2010 | March 2012 | Allow | 25 | 0 | 0 | Yes | No |
| 12439431 | Method for Improving the Specific Effector Function of Single-Chain Antigen-Recognizing Genetic Constructs (SCARC) Through Murinization Thereof | November 2009 | February 2016 | Allow | 60 | 5 | 1 | Yes | Yes |
| 12610815 | MONOCYTES AS A GENE DELIVERY VECTOR FOR SECRETED PROTEINS TO TREAT ALZHEIMER'S DISEASE | November 2009 | February 2013 | Allow | 40 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEHBE, ANNE MARIE SABRINA.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WEHBE, ANNE MARIE SABRINA works in Art Unit 1634 and has examined 168 patent applications in our dataset. With an allowance rate of 89.3%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner WEHBE, ANNE MARIE SABRINA's allowance rate of 89.3% places them in the 71% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by WEHBE, ANNE MARIE SABRINA receive 2.71 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WEHBE, ANNE MARIE SABRINA is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +14.0% benefit to allowance rate for applications examined by WEHBE, ANNE MARIE SABRINA. This interview benefit is in the 52% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.7% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 60.4% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 93.1% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 87.9% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 17.3% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.